TY  - JOUR
PY  - 2022//
TI  - Esketamine for treatment-resistant depression in adults
JO  - Cochrane database of systematic reviews
A1  - Gastaldon, C.
A1  - Laurenzi, P.F.
A1  - Schoretsanitis, G.
A1  - Papola, D.
A1  - Cristea, I.A.
A1  - Naudet, F.
A1  - Ostuzzi, G.
A1  - Barbui, C.
SP  - 
EP  - 
VL  - 2022
IS  - 1
N2  - OBJECTIVES: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. The main aim of this Cochrane review is to assess the efficacy and tolerability of esketamine for treatment-resistant depression. Secondary aims are to assess the risk of specific adverse events during esketamine treatment, and its acceptability. Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.<p /> <p>Language: en</p>
LA  - en
SN  - 1465-1858
UR  - http://dx.doi.org/10.1002/14651858.CD015071
ID  - ref1
ER  -